JCEM:膳食锌摄入量与新发糖尿病之间的U型关联

2021-08-30 MedSci原创 MedSci原创

膳食中锌摄入量与一般中国成人新发糖尿病之间存在U型关联,其拐点约为9.1 mg/天。

近日,内分泌和代谢性疾病领域权威杂志Journal of Clinical Endocrinology & Metabolism上发表了一篇研究文章,研究人员旨在调查中国成年人膳食锌摄入量与新发糖尿病之间的关系。

该研究纳入了16257名中国健康与营养调查(CHNS)研究中基线未患糖尿病的参与者。膳食摄入量是通过3次连续24小时膳食召回结合家庭食品库存来衡量的。随访期间自我报告的且经医生诊断为糖尿病、空腹血糖≥7.0mmol/L或糖化血红蛋白≥6.5%的参与者被定义为新发糖尿病患者。该研究的中位随访时间为9.0年。

总体而言,膳食锌摄入量与新发糖尿病之间的关联呈U型(非线性P<0.001)。锌摄入量<9.1 mg/天(每mg/天:HR为0.73;95%CI为0.60-0.88)的参与者新发糖尿病的风险显著降低,而锌摄入量≥9.1mg/天的参与者则更高(每mg/天:HR为1.10;95%CI为1.07-1.13)。

当膳食锌摄入量按照十分位数进行评估时,相比于第2-8个十分位数(8.9-12.2mg/天)相比,第1个十分位数(<8.9 mg/天:HR为1.29;95%CI为1.04-1.62)和第9-10个十分位数(≥12.2mg/天:HR为1.62;95%CI为1.38-1.90)的个体患糖尿病的风险更高。植物源性或动物源性锌摄入量与新发糖尿病之间也观察到了类似的U型关系(所有非线性P<0.001)。

由此可见,膳食中锌摄入量与一般中国成人新发糖尿病之间存在U型关联,其拐点约为9.1 mg/天。

原始出处:

Panpan He.et al.U-shaped association between dietary zinc intake and new-onset diabetes: A nationwide cohort study in China.JCEM.2021.https://doi.org/10.1210/clinem/dgab636

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2063493, encodeId=643d2063493e8, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Mon Aug 15 21:58:36 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860714, encodeId=75211860e141d, content=<a href='/topic/show?id=830b5693631' target=_blank style='color:#2F92EE;'>#摄入量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56936, encryptionId=830b5693631, topicName=摄入量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Mon May 23 21:58:36 CST 2022, time=2022-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778111, encodeId=093b1e78111d3, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri May 13 13:58:36 CST 2022, time=2022-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350448, encodeId=9f02135044868, content=<a href='/topic/show?id=224a85904ad' target=_blank style='color:#2F92EE;'>#膳食#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85904, encryptionId=224a85904ad, topicName=膳食)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Sep 01 09:58:36 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043768, encodeId=23641043e68ca, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Aug 30 21:58:36 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012987, encodeId=1045101298efb, content=每日评论很有意思学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16a15589215, createdName=谢尔比, createdTime=Mon Aug 30 20:58:06 CST 2021, time=2021-08-30, status=1, ipAttribution=)]
    2022-08-15 achengzhao
  2. [GetPortalCommentsPageByObjectIdResponse(id=2063493, encodeId=643d2063493e8, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Mon Aug 15 21:58:36 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860714, encodeId=75211860e141d, content=<a href='/topic/show?id=830b5693631' target=_blank style='color:#2F92EE;'>#摄入量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56936, encryptionId=830b5693631, topicName=摄入量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Mon May 23 21:58:36 CST 2022, time=2022-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778111, encodeId=093b1e78111d3, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri May 13 13:58:36 CST 2022, time=2022-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350448, encodeId=9f02135044868, content=<a href='/topic/show?id=224a85904ad' target=_blank style='color:#2F92EE;'>#膳食#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85904, encryptionId=224a85904ad, topicName=膳食)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Sep 01 09:58:36 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043768, encodeId=23641043e68ca, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Aug 30 21:58:36 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012987, encodeId=1045101298efb, content=每日评论很有意思学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16a15589215, createdName=谢尔比, createdTime=Mon Aug 30 20:58:06 CST 2021, time=2021-08-30, status=1, ipAttribution=)]
    2022-05-23 lmm397
  3. [GetPortalCommentsPageByObjectIdResponse(id=2063493, encodeId=643d2063493e8, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Mon Aug 15 21:58:36 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860714, encodeId=75211860e141d, content=<a href='/topic/show?id=830b5693631' target=_blank style='color:#2F92EE;'>#摄入量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56936, encryptionId=830b5693631, topicName=摄入量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Mon May 23 21:58:36 CST 2022, time=2022-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778111, encodeId=093b1e78111d3, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri May 13 13:58:36 CST 2022, time=2022-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350448, encodeId=9f02135044868, content=<a href='/topic/show?id=224a85904ad' target=_blank style='color:#2F92EE;'>#膳食#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85904, encryptionId=224a85904ad, topicName=膳食)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Sep 01 09:58:36 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043768, encodeId=23641043e68ca, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Aug 30 21:58:36 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012987, encodeId=1045101298efb, content=每日评论很有意思学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16a15589215, createdName=谢尔比, createdTime=Mon Aug 30 20:58:06 CST 2021, time=2021-08-30, status=1, ipAttribution=)]
    2022-05-13 仁者大医
  4. [GetPortalCommentsPageByObjectIdResponse(id=2063493, encodeId=643d2063493e8, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Mon Aug 15 21:58:36 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860714, encodeId=75211860e141d, content=<a href='/topic/show?id=830b5693631' target=_blank style='color:#2F92EE;'>#摄入量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56936, encryptionId=830b5693631, topicName=摄入量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Mon May 23 21:58:36 CST 2022, time=2022-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778111, encodeId=093b1e78111d3, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri May 13 13:58:36 CST 2022, time=2022-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350448, encodeId=9f02135044868, content=<a href='/topic/show?id=224a85904ad' target=_blank style='color:#2F92EE;'>#膳食#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85904, encryptionId=224a85904ad, topicName=膳食)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Sep 01 09:58:36 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043768, encodeId=23641043e68ca, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Aug 30 21:58:36 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012987, encodeId=1045101298efb, content=每日评论很有意思学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16a15589215, createdName=谢尔比, createdTime=Mon Aug 30 20:58:06 CST 2021, time=2021-08-30, status=1, ipAttribution=)]
    2021-09-01 zhaojie88
  5. [GetPortalCommentsPageByObjectIdResponse(id=2063493, encodeId=643d2063493e8, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Mon Aug 15 21:58:36 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860714, encodeId=75211860e141d, content=<a href='/topic/show?id=830b5693631' target=_blank style='color:#2F92EE;'>#摄入量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56936, encryptionId=830b5693631, topicName=摄入量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Mon May 23 21:58:36 CST 2022, time=2022-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778111, encodeId=093b1e78111d3, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri May 13 13:58:36 CST 2022, time=2022-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350448, encodeId=9f02135044868, content=<a href='/topic/show?id=224a85904ad' target=_blank style='color:#2F92EE;'>#膳食#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85904, encryptionId=224a85904ad, topicName=膳食)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Sep 01 09:58:36 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043768, encodeId=23641043e68ca, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Aug 30 21:58:36 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012987, encodeId=1045101298efb, content=每日评论很有意思学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16a15589215, createdName=谢尔比, createdTime=Mon Aug 30 20:58:06 CST 2021, time=2021-08-30, status=1, ipAttribution=)]
    2021-08-30 misszhang

    谢谢MedSci提供最新的资讯

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2063493, encodeId=643d2063493e8, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Mon Aug 15 21:58:36 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860714, encodeId=75211860e141d, content=<a href='/topic/show?id=830b5693631' target=_blank style='color:#2F92EE;'>#摄入量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56936, encryptionId=830b5693631, topicName=摄入量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Mon May 23 21:58:36 CST 2022, time=2022-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778111, encodeId=093b1e78111d3, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri May 13 13:58:36 CST 2022, time=2022-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350448, encodeId=9f02135044868, content=<a href='/topic/show?id=224a85904ad' target=_blank style='color:#2F92EE;'>#膳食#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85904, encryptionId=224a85904ad, topicName=膳食)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Sep 01 09:58:36 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043768, encodeId=23641043e68ca, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Aug 30 21:58:36 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012987, encodeId=1045101298efb, content=每日评论很有意思学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16a15589215, createdName=谢尔比, createdTime=Mon Aug 30 20:58:06 CST 2021, time=2021-08-30, status=1, ipAttribution=)]
    2021-08-30 谢尔比

    每日评论很有意思学习了

    0

相关资讯

JCEM:胰岛素分泌可预测新发糖尿病患者对降糖治疗的反应

葡萄糖负荷后空腹血浆C肽浓度的增加预示着新发糖尿病患者对降糖治疗的反应。C-Pep120/C-Pep0为新发糖尿病患者的降糖治疗个体化方案提供了有用的工具。

Diabetic Med:高血压患者治疗时HDL低预示新发糖尿病风险更高

  既往研究表明,基线高密度脂蛋白胆固醇(HDL-C)水平较低的高血压患者发生糖尿病的风险增加。美国纽约威尔康奈尔医学院Peter M. Okin等开展的一项研究表明,与基线HDL-C水平较低者相比,治疗期间HDL-C水平仍较低者新发糖尿病的风险更大。(Diabetic Med. 2013年4月16日在线版)   该研究纳入7485例无糖尿病史的高血压患者

Gastroenterology:新发糖尿病患者胰腺导管腺癌筛查有新方法啦!

研究者开发了一个基于广泛使用的临床参数的风险模型来帮助确定新发糖尿病患者中可以从PDA筛选中受益的个体。

JACC:阿托伐他汀与新发糖尿病相关性受基线危险因素影响

  美国学者的一项研究表明,在新发糖尿病(NOD)低风险(无或1项NOD危险因素)患者中,大剂量阿托伐他汀(80 mg/天)未升高NOD发病率,但在高风险(2—4项NOD危险因素)患者中则增加24%的NOD风险;研究进一步表明,80 mg阿托伐他汀可明显减少以上两种风险人群的心血管疾病事件(CV)。论文发表于《美国心脏病学会杂志》[J Am Coll&nbs

CFDA通知要求修订普伐他汀说明书

为适应科学用药需要,保障公众用药安全,经研究,国家食品药品监督管理总局(CFDA)决定对普伐他汀钠片和胶囊说明书【注意事项】项下的相关内容进行修订。修订要求如下         普伐他汀钠片和胶囊说明书修订要求 【注意事项】 增加如下内容: 有报道显示,其他HMG-CoA还原酶抑制剂的使用与

J Hypertens:抗高血压治疗对高危高血压患者心血管事件和新发糖尿病的长期影响!

由此可见,在超过28385人次每年的患者随访中,研究人员证实了坎地沙坦和氨氯地平在降低高危高血压患者心血管事件方面具有相当的效果。此外,该研究的结果支持坎地沙坦在减少NOD发病率方面优于氨氯地平,即使进行长期随访。